Keyword Analysis & Research: apixaban dosing uptodate
Keyword Research: People who searched apixaban dosing uptodate also searched
Search Results related to apixaban dosing uptodate on Search Engine
-
Direct oral anticoagulants (DOACs) and parenteral direct ... - UpToDate
https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects
webMar 1, 2024 · - Factor Xa inhibitors dosing - Factor Xa inhibitors toxicity - High BMI and post-bariatric surgery; Rivaroxaban - Overview (rivaroxaban) - Dosing, monitoring, risks (rivaroxaban) Apixaban - Overview (apixaban) - Dosing, monitoring, risks (apixaban) Edoxaban - Overview (edoxaban) - Dosing, monitoring, risks (edoxaban) Betrixaban
DA: 14 PA: 29 MOZ Rank: 13
-
Atrial fibrillation in adults: Use of oral anticoagulants - UpToDate
https://www.uptodate.com/contents/atrial-fibrillation-in-adults-use-of-oral-anticoagulants
webMar 8, 2024 · Most patients with atrial fibrillation (AF) should receive long-term oral anticoagulation to decrease the risk of ischemic stroke and other embolic events. For most patients, the benefit from anticoagulation outweighs the associated increase in …
DA: 16 PA: 71 MOZ Rank: 91
-
Apixaban - StatPearls - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK507910/
webLast Update: April 19, 2023. Go to: Continuing Education Activity. Apixaban is a novel oral anticoagulant (NOAC) approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with non-valvular atrial fibrillation to reduce the risk of stroke and blood clots.
DA: 7 PA: 40 MOZ Rank: 16
-
Venous thromboembolism: Anticoagulation after initial management - UpToDate
https://www.uptodate.com/contents/venous-thromboembolism-anticoagulation-after-initial-management
webJun 7, 2023 · Following initial anticoagulation for the first 5 to 10 days, patients with VTE require therapy for a more prolonged period. This topic review will discuss the selection of an anticoagulant, the transition from initial therapy, and the …
DA: 78 PA: 65 MOZ Rank: 17
-
UpToDate
https://sso.uptodate.com/contents/image?imageKey=PI/99882
webHow often do I need to take it? Once a day. Once or twice a day, depending on the reason for taking it. Apixaban – Once or twice a day, depending on the reason for taking it. Edoxaban – Once a day. Rivaroxaban – Once a day (some people may need to take it twice a day for the first 3 weeks).
DA: 23 PA: 20 MOZ Rank: 17
-
Management of bleeding in patients receiving direct oral ... - UpToDate
https://www.uptodate.com/contents/management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants
webFeb 16, 2024 · Management of bleeding in patients receiving direct oral anticoagulants - UpToDate. Learn how UpToDate can help you. Select the option that best describes you. Medical Professional. Resident, Fellow, or Student. Hospital or Institution. Group Practice. Patient or Caregiver. Management of bleeding in patients receiving direct oral …
DA: 7 PA: 91 MOZ Rank: 100
-
Coronary artery disease patients requiring combined ... - UpToDate
https://www.uptodate.com/contents/coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy
webMay 30, 2023 · This topic will provide the clinician with a guide for choosing a reasonable antithrombotic regimen for CAD patients with an indication for combined antithrombotic therapy after coronary artery stenting. Patients with an ACS treated medically (no stenting) who need oral anticoagulation are discussed separately.
DA: 98 PA: 48 MOZ Rank: 9
-
Practical management of patients on apixaban: a consensus guide
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904756/
webDec 31, 2013 · Apixaban is a direct factor Xa inhibitor with a 12-hour half-life and 25% renal excretion that was found in a large trial of NVAF patients to be superior to warfarin in preventing stroke or systemic embolism. In this trial population, apixaban also resulted in less bleeding and a lower mortality rate than warfarin. Methods.
DA: 49 PA: 89 MOZ Rank: 65
-
UpToDate
https://us.uptodate.com/contents/overview-of-the-treatment-of-proximal-and-distal-lower-extremity-deep-vein-thrombosis-dvt/abstract/8
webThe non-vitamin K antagonist oral anticoagulants (NOACs), including the factor Xa inhibitors apixaban, edoxaban and rivaroxaban as well as the direct-thrombin inhibitor dabigatran, are increasing the convenience of and options available for VTE treatment.
DA: 69 PA: 34 MOZ Rank: 74
-
UpToDate
https://sso.uptodate.com/contents/apixaban-drug-information
webApixaban is a direct oral anticoagulant that is used to prevent and treat blood clots in various conditions. Learn about its indications, dosing, interactions, adverse effects, and management of bleeding from UpToDate, a trusted source of …
DA: 62 PA: 44 MOZ Rank: 7